New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival
- Analysis of combination therapy demonstrated statistically significant prolongation of survival in a patient-derived xenograft (PDX) model
-
Abstract published online today in advance of virtual meeting of the
Society of Hematologic Oncology (SOHO) taking placeSeptember 9-12, 2020
The data presented are from an animal model created using tissue derived from a patient who had developed resistance to venetoclax/HMA. In this model, the addition of uproleselan to the treatment regimen demonstrated robust anti-leukemic activity and a statistically significant prolongation of survival. The research strongly supports the opportunity for additional clinical evaluation of the triple combination of uproleselan, venetoclax and HMA in the frontline, unfit AML patient population.
“We know that binding leukemic cells to E-selectin within the bone marrow niche up-regulates pro-survival mechanisms. This preclinical study shows that by blocking this activity with uproleselan, we can enhance the sensitivity to venetoclax/HMAs. This supports using this treatment regimen to potentially improve outcomes in patients whose duration of response is typically very short,” said
Visit the meeting’s website for more information: https://www.soho2020.com/., The virtual meeting will be held
About Uproleselan (GMI-1271)
Discovered and developed by
About
Forward-Looking Statements
This press release contains forward-looking statements regarding the Company’s strategy and the clinical development and potential utility, benefits and impact of its drug candidates. These forward-looking statements include those relating to the planned preclinical research and clinical development of the Company’s product candidates. Actual results may differ materially from those expressed in or implied by these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005303/en/
Investor Contact:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: